Bonilla-Jaime H, Retana-Marquez S, Velazquez-Moctezuma J
Biology of Reproduction, Universidad Autonoma Metropolitana-Iztapalapa, México City, México.
Pharmacol Biochem Behav. 1998 May;60(1):39-45. doi: 10.1016/s0091-3057(97)00484-x.
Neonatal treatment with clomipramine induces behavioral alterations during adulthood that resemble symptoms observed in human depression. Therefore, it has been proposed as an animal model of depression. Impairment of male sexual performance is one of the main effects of this treatment. Using this model of depression, we evaluated the effects of drugs that stimulate sexual performance by acting selectively on the adrenergic, serotonergic, or cholinergic system. Yohimbine, a selective antagonist of the alpha-2 receptors; 8-OH-DPAT, a selective agonist of the 5-HT1A receptors; and oxotremorine, a muscarinic agonist, were administered to male rats neonatally treated with clomipramine that showed sexual behavior impairments. Yohimbine and oxotremorine induced only a slight improvement of sexual deficiencies. 8-OH-DPAT not only restored sexual behavior to normal levels, but induced facilitation in most of the copulatory parameters. These results suggest that neonatal treatment with clomipramine induces sexual deficits acting mainly on the adrenergic and cholinergic systems, while the serotoninergic system seems to be preserved.
氯米帕明的新生儿期治疗会在成年期引发行为改变,这些改变类似于人类抑郁症中观察到的症状。因此,它被提议作为抑郁症的动物模型。男性性功能受损是这种治疗的主要影响之一。利用这种抑郁症模型,我们评估了通过选择性作用于肾上腺素能、血清素能或胆碱能系统来刺激性功能的药物的效果。育亨宾是一种α-2受体的选择性拮抗剂;8-羟基二丙胺基四氢萘(8-OH-DPAT)是一种5-羟色胺1A(5-HT1A)受体的选择性激动剂;氧化震颤素是一种毒蕈碱激动剂,将它们给予接受过氯米帕明新生儿期治疗且表现出性行为受损的雄性大鼠。育亨宾和氧化震颤素仅使性缺陷略有改善。8-OH-DPAT不仅将性行为恢复到正常水平,还在大多数交配参数上诱导了促进作用。这些结果表明,氯米帕明的新生儿期治疗导致性缺陷,主要作用于肾上腺素能和胆碱能系统,而血清素能系统似乎未受影响。